AAA617 not checked

Novartis · Lu-PSMA-617 · 177Lu-PSMA-617

FollowEvery change as it happens, and a Monday email
Next date
Phase 2 trial completes
Trials
18 active
24 in total · 21 in the EU
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“Long-term follow-up (LTFU) safety study of adult participants with prostate cancer that have received at least one dose of AAA617 from parent interventional Novartis sponsored clinical trials.”In the company’s words, NCT05803941 on ClinicalTrials.gov
Tested for
Metastatic Castration-Resistant Prostate Cancer (mCRPC) (2 trials), Prostate Cancer, Prostatic Neoplasms, Oligometastatic Prostate Cancer (OMPC), Metastatic Castration Resistant Prostate Cancer (mCRPC), Prostatic Neoplasm, Prostatic Cancer, Castration-Resistant, Metastatic Castration-Resistant Prostate Cancer
Main trialPhase 4
“The purpose of this post-marketing study is to further characterize the long-term outcome of known or potential risks of lutetium (177Lu) vipivotide tetraxetan also known as \[177Lu\]Lu-PSMA-617 or 177Lu-PSMA-617 and hereinafter referred to as AAA617. The study also seeks to further characterize (as possible) any other AAA617 causally related serious adverse event(s) in the long-term in adults with prostate cancer who received at least one dose of AAA617 from interventional, Phase I-IV Novartis sponsored clinical trials.”In the company’s words, NCT05803941 on ClinicalTrials.gov
Other names
Lu-PSMA-617 · Pluvicto · 177Lu-PSMA-617

Other drugs for Metastatic Castration-Resistant Prostate Cancer (mCRPC)

All 25 drugs for Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Coming up5

Changes4

Last 90 days

Trials24

TrialPhaseCompletesWhat it tests
Phase 4Recruiting 20 Jul 2033 Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer
Phase 3Active, not recruiting 13 Jan 2025 An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
Phase 3Recruiting 25 Apr 2028 An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.
Phase 2Active, not recruiting 2 Dec 2024 A Study Evaluating [177Lu]Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in Taxane Treatment Naive Chinese Male Patients With Progressive Metastatic Castrate Resistant Prostate Cancer
Phase 2Active, not recruiting 6 Nov 2026 Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function
Phase 2Active, not recruiting 17 Nov 2026 An Open-label Study of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPC
Phase 2Active, not recruiting 23 Dec 2026 A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC
Phase 2Active, not recruiting 16 Jul 2027 A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
Phase 1Active, not recruiting 24 Apr 2029 A Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment in Chemo-naïve Adults With Metastatic Castration-resistant Prostate Cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) Study
Phase 3Completed 2 Oct 2022 177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer
Phase 2Completed 17 May 2024 A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Dosimetry of [177Lu]Lu-PSMA-617 in Chinese Adult Male Patients With Progressive PSMA-Positive mCRPC
Phase 1Terminated 16 Oct 2026 NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.
Phase 1/2Authorised not given A Phase I/II Study of Neoadjuvant, Intra-arterial Administration of [177Lu]Lu-PSMA-617 in Subjects with High-risk, Localised or Locally Advanced Prostate Cancer who are Candidates for Radical Prostatectomy (LUPUS)
Phase 3Authorised not given PEACE-6 Poor Responders: A randomized phase III trial evaluating the efficacy and safety of 177Lu-PSMA-617 in addition to Standard of Care (SoC) versus SoC alone in de novo metastatic hormone-sensitive prostate cancer (mHSPC) patients having a serum PSA level of ≥ 0.2 ng/mL at 6 to 8 months after systemic treatment initiation for mHSPC.
Phase 2Ended not given The evaluation of the effectiveness, safety and tolerability of treatment, using a specialized prostate-specific membrane antigen (PSMA) labeled with Lutetium177, in patients with recurrent and/or metastatic adenoid cystic carcinoma originating from the salivary glands - an open, non-commercial clinical trial
Phase 2Authorised not given 177Lu-PSMA as a systemic adjuvant treatment in patients with high and very high risk prostate cancer after radical treatment with locoregional teleradiotherapy and hormone therapy.
Phase 2Ended not given Lutetium-177-PSMA in Oligo-metastatic Hormone Sensitive Prostate Cancer.
Phase 2Authorised not given ReaLuP : an open label, single arm phase IIb study of re-treatment with [177Lu]Lu-PSMA in men with metastatic castration resistance prostate cancer
Phase 1Ended not given A phase I study of neoadjuvant treatment with 177-Lutetium-PSMA-617 with Ipilimumab in subjects with very high-risk prostate cancer who are candidates for radical prostatectomy (NEPI Trial)
Phase 2Authorised not given EORTC-2361-GUCG: Phase II trial evaluating the efficacy of 177Lutetium-PSMA treatment in patients with metastatic clear cell Renal Carcinoma Cell with progressive disease on first-line or second-line systemic treatment (RENALUT)
Phase 3Authorised not given Studying Treatments in patients receiving androgen deprivation therapy (ADT) for Metastatic Prostate Cancer: Evaluation of Drug and radiation Efficacy: A 2nd multi-arm multi-stage randomised controlled trial (STAMPEDE2)
Phase 1Authorised not given An open-label, multicentric, phase 1 study to evaluate the safety, tolerability, and radiation dosimetry of endogenous radioligand therapy with (¹⁷⁷Lu)Lutetiumvipivotidtetraxetan in women with metastatic triple negative breast cancer (TNBC)
Phase 2Authorised not given Phase 2, open-label, randomized study to investigate safety and efficacy of Pluvicto® therapy in patients with metastatic hormone-sensitive prostate cancer in addition to standard of care treatment with Nubeqa® and ADT (ARALU)
Phase 2Authorised not given Evaluation of the efficacy, safety, and tolerability of lutetium-177-labeled PSMA ligand in patients with progression of adenoid cystic carcinoma originating from the salivary glands - an open, non-commercial clinical trial
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow AAA617

Following is part of Solo: you see every change to AAA617 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in